Response to: 'Off-label use of tofacitinib: a potential treatment option for SAPHO syndrome' by Xie et al

Ann Rheum Dis. 2022 Jun;81(6):e92. doi: 10.1136/annrheumdis-2020-217956. Epub 2020 Jun 11.

¹ Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China.
² Department of Radiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
³ Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China casio1981@163.com zhangwen91@sina.com.
⁴ Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China casio1981@163.com zhangwen91@sina.com.

No abstract available

Keywords: antirheumatic agents; autoimmune diseases; synovitis.

Publication types